Drugs / COH04S1
COH04S1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05672355 | Aug 2023 → Jan 2029 | B-cell chronic lymphocytic leukemia, COVID-19 | City of Hope Medical Center | Suspended | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COH04S1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05672355 ↗ |
| Known as | SARS-CoV-2 Vaccine COH04S1 | “SARS-CoV-2 Vaccine COH04S1” NCT05672355 ↗ |
| Known as | sMVA-based SARS-CoV-2 Vaccine COH04S1 | “sMVA-based SARS-CoV-2 Vaccine COH04S1” NCT05672355 ↗ |
| Modality | Vaccine | “synthetic MVA-based SARS-CoV-2 vaccine COH04S1” NCT05672355 ↗ |
| Route | Intramuscular | “intramuscularly (IM)” NCT05672355 ↗ |